Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092613 - METHODS FOR PREDICTING RESPONSE TO TEMOZOLOMIDE THERAPY FOR PATIENTS WITH COLON CANCER

Publication Number WO/2020/092613
Publication Date 07.05.2020
International Application No. PCT/US2019/058919
International Filing Date 30.10.2019
IPC
G01N 33/94 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
94involving narcotics
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
G01N 30/72 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
30Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
02Column chromatography
62Detectors specially adapted therefor
72Mass spectrometers
C12Q 1/48 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
48involving transferase
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Applicants
  • NANTOMICS, LLC [US]/[US]
Inventors
  • SZETO, Christopher
  • VERRAPANENI, Saihitha
  • BENZ, Stephen C.
Agents
  • FESSENMAIER, Martin
  • PHUKAN, Priti D.
  • DEAN, Ryan S.
  • BALLEW-CHANG, Nicole
Priority Data
62/753,68731.10.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR PREDICTING RESPONSE TO TEMOZOLOMIDE THERAPY FOR PATIENTS WITH COLON CANCER
(FR) PROCÉDÉS DE PRÉDICTION DE LA RÉPONSE À UNE THÉRAPIE PAR TÉMOZOLOMIDE POUR DES PATIENTS ATTEINTS D'UN CANCER DU CÔLON
Abstract
(EN)
Contemplated systems and methods use a response prediction model for temozolomide (TMZ) sensitivity for treating a tumor in a patient that is based on data obtained for O-6-methylguanine-DNA methyltransferase (MGMT) from the tumor. Example MGMT data includes promoter methylation status, RNA-seq information, and protein quantitative information to obtain a TMZ response prediction accuracy of at least 80%.
(FR)
L'invention concerne des systèmes et des procédés utilisant un modèle de prédiction de réponse pour la sensibilité au témozolomide (TMZ) en vue de traiter une tumeur chez un patient, qui est basé sur des données obtenues pour la O-6-méthylguanine-ADN méthyltransférase (MGMT) à partir de la tumeur. Des exemples de données pour la MGMT comprennent un état de méthylation du promoteur, des informations d'ARN-seq et des informations quantitatives de protéine pour obtenir une précision de prédiction de la réponse au TMZ d'au moins 80 %.
Latest bibliographic data on file with the International Bureau